Covidien (NYSE: COV) announces 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LigaSure™ Curved, Small Jaw, Open Sealer/Divider surgical instrument. The device is indicated for use in general surgery and will be available in the United States this quarter.
The LigaSure Curved, Small Jaw, Open Sealer/Divider, the newest addition to the LigaSure family of advanced surgical cutting/sealing devices, provides an integrated cutting mechanism independent of sealing, leaving the critical cutting decisions in the hands of the surgeon. Its multi-functional design also provides for blunt dissection and an enhanced, more efficient experience for the surgeon, especially in confined surgical spaces. A primary feature of this new LigaSure device is a low-temperature profile and minimal thermal spread to surrounding tissues.
The LigaSure technology, powered by the ForceTriad™ energy platform, provides surgeons with a continuous output of energy, monitoring the tissue and making real-time adjustments 3,333 times/second to seal vessel walls. LigaSure technology has been in use for 12 years, and is utilized in more than one million procedures around the world each year.
For more information, visit www.covidien.com